| Event Value | ₹832.50 CrLicensing Deal |
|---|---|
| Market Cap | ₹1,01,735 CrLarge Cap |
| Revenue TTM | ₹29,967 CrOperating |
| RSI | 31.49Near Oversold |
| Execution period | Initial term until 20th anniversary of first commercial sale |
| Deal value | ₹832.5 Cr |
| Share of market cap | 0.8% |
| Share of annual revenue | 2.8% |
Key highlights
- Exclusive license for EU, UK, Switzerland, Norway, and Iceland territories
- Total potential consideration of 75 million euros or approximately ₹832.50 crore
- Financials include a 20 million euro strategic investment and 55 million euro in milestones
- Initial agreement term spans 20 years from the date of first commercial sale per country
- YUVEZZI is the first FDA-approved once-daily dual-agent eye drop for adult presbyopia
Strategic Licensing and Investment Details
VISUfarma B.V., a Dutch subsidiary of Lupin Limited, has entered an exclusive license agreement with U.S.-based Visus Therapeutics for the proprietary ophthalmic product YUVEZZI. The deal grants VISUfarma rights for regulatory activities, marketing, and distribution across the European Union, United Kingdom, Switzerland, Norway, and Iceland. Under the terms, VISUfarma will make a 20 million euro strategic investment in Visus or its parent through a Simple Agreement for Future Equity instrument.
Additionally, the partner is eligible for up to 55 million euro in regulatory and commercial milestone payments, alongside tiered royalties based on net sales performance once commercialization begins in the licensed territories.
Market Significance of YUVEZZI
This partnership marks a significant expansion of Lupin’s specialty care strategy in the European vision management segment. YUVEZZI is recognized as the first and only FDA-approved once-daily, dual-agent eye drop indicated for presbyopia, a condition affecting nearly 2 billion people globally. By securing these rights, Lupin aims to address unmet patient needs in the aging eye category while creating long-term growth opportunities.
The 20-year initial term per country ensures a sustained revenue stream potential from this differentiated therapy, reinforcing Lupin's leadership in the ophthalmology space across major European jurisdictions and providing access to a novel therapy for millions of patients.
Financial Position and Performance
Lupin Limited continues to demonstrate strong financial growth, reporting an annual operating revenue of ₹27,958.03 crore and a net profit of ₹5,332.84 crore. The company's quarterly revenue grew by 32.04 percent year-on-year, significantly outperforming the pharmaceutical sector average of 15.52 percent. With a market capitalization exceeding ₹1 lakh crore and a durability score of 80, the company maintains a robust position to fund international expansions.
This latest licensing agreement aligns with Lupin's objective to strengthen its specialty ophthalmology portfolio, which currently complements its diversified presence in generics and complex biosimilars across 15 state-of-the-art manufacturing facilities globally.
Management Perspective
Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories.
“We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy.”
“Lupin’s strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma’s longstanding presence in eyecare makes them an excellent partner.”
| Share price | ₹2225 |
|---|---|
| Market capitalisation | ₹1.02L Cr |
| Revenue (annual) | ₹27,958.03 Cr |
| Net profit (annual) | ₹5,332.84 Cr |
| Revenue (latest quarter) | ₹8,276.89 Cr+10.73% vs previous quarter |
| Net profit (latest quarter) | ₹1,415.00 Cr-3.10% vs previous quarter |
| P/E (TTM) | 18.4×Sector 45.61× |
| Promoter holding | 46.85%-0.01% QoQ |
| FII holding | 22.42%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Lupin Limited announcing a strategic partnership to commercialize YUVEZZI in Europe through its subsidiary VISUfarma. Market figures from a third-party data provider.
